微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > oncolytic adenovirus
oncolytic adenovirus

免疫

关键词免疫 临床研究术语 病毒

词汇介绍

拓展阅读

解析

oncolytic  英  /'wʌnkəlaɪtɪk/  美  /'wʌnkəlaɪtɪk/

释    义   adj. 溶瘤细胞的

例    句   This new oncolytic adenovirus mutant has good clinical prospect in gene curing so to used in curing many kinds of human tumors.该新型溶瘤腺病毒突变体在基因治疗中具有良好的临床应用前景,可用于多种人体肿瘤的治疗。

 

adenovirus  英  /'ædɪnəʊ,vaɪrəs/  美  /ə,dino'vaɪrəs/

释    义   n. 腺病毒

例    句   Rotavirus is the major etiologic agents of acute gastroenteritis in infants and young children, astrovirus and enteral adenovirus are the secondly agents and there are mixed infections.轮状病毒是婴幼儿秋季腹泻的主要原因,其次是肠道腺病毒及星状病毒,且存在混合感染情况。

概述

  溶瘤病毒是指能够选择性在肿瘤细胞中复制并使其裂解,而不伤害正常细胞的病毒。有些为天然病毒,如:New castle disease virus、myxoma viruses、Seneca Valley virus和coxsackie virus等,这些病毒通常具有干扰素敏感性。另外一类则是通过基因修饰使其具有肿瘤选择性,如:腺病毒、单纯疱疹病毒、麻疹病毒、脊髓灰质炎病毒和水泡性口炎病毒等。病毒感染复制破坏肿瘤细胞产生直接抗肿瘤作用,在这种情况下,病毒的释放和危

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.复制标题

DNX-2401 (Delta-24-RGD) 溶瘤腺病毒的I期研究: 复发恶性胶质瘤的复制和免疫治疗作用。

发表时间:2018-05-10

影响因子:28.2

作者: Lang FF

期刊:J Clin Oncol

Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but the effects and mechanisms of action have not been evaluated in patients. Methods A phase I, dose-escalation, biologic-end-point clinical trial of DNX-2401 was conducted in 37 patients with recurrent malignant glioma. Patients received a single intratumoral injection of DNX-2401 into biopsy-confirmed recurrent tumor to evaluate safety and response across eight dose levels (group A). To investigate the mechanism of action, a second group of patients (group B) underwent intratumoral injection through a permanently implanted catheter, followed 14 days later by en bloc resection to acquire post-treatment specimens. Results In group A (n = 25), 20% of patients survived > 3 years from treatment, and three patients had a ≥ 95% reduction in the enhancing tumor (12%), with all three of these dramatic responses resulting in > 3 years of progression-free survival from the time of treatment.

译文

目的dnx - 2401 (Delta-24-RGD;tasadenoturev)是一种肿瘤选择性、复制能力强的溶瘤腺病毒。临床前研究证实了抗胶质瘤的疗效,但其作用机制尚未在患者中进行评估。方法对37例复发恶性胶质瘤患者进行一期、剂量递增、生物终点临床试验。患者接受单个瘤内注射dnx - 2401活检确诊复发肿瘤评估安全性和响应在8个剂量水平(a组)。调查行动的机制,第二组患者(B组)进行了通过永久植入导管瘤内注射,之后14天,全体切除收购后处理标本。结果在A组(n = 25), 20%的患者存活3年>从治疗,和三个患者减少≥95%提高肿瘤(12%),与所有三个戏剧性的反应导致> 3年无进展生存时间的治疗。